Document is current
Any future updates will be listed below
-
Authors
Groha, Stefan
Alaiwi, Sarah Abou http://orcid.org/0000-0002-7073-3432
Xu, Wenxin http://orcid.org/0000-0002-8450-2037
Naranbhai, Vivek
Nassar, Amin H. http://orcid.org/0000-0002-8084-9105
Bakouny, Ziad http://orcid.org/0000-0003-1906-5704
El Zarif, Talal http://orcid.org/0000-0002-4507-2396
Saliby, Renee Maria
Wan, Guihong http://orcid.org/0000-0003-1100-4018
Rajeh, Ahmad
Adib, Elio
Nuzzo, Pier V. http://orcid.org/0000-0002-5618-8079
Schmidt, Andrew L.
Labaki, Chris
Ricciuti, Biagio
Alessi, Joao Victor
Braun, David A.
Shukla, Sachet A. http://orcid.org/0000-0003-2445-3584
Keenan, Tanya E.
Van Allen, Eliezer http://orcid.org/0000-0002-0201-4444
Awad, Mark M.
Manos, Michael
Rahma, Osama
Zubiri, Leyre
Villani, Alexandra-Chloe
Fairfax, Benjamin http://orcid.org/0000-0001-7413-5002
Hammer, Christian
Khan, Zia http://orcid.org/0000-0002-7859-3489
Reynolds, Kerry
Semenov, Yevgeniy http://orcid.org/0000-0002-7387-3094
Schrag, Deborah
Kehl, Kenneth L. http://orcid.org/0000-0001-5339-9797
Freedman, Matthew L. http://orcid.org/0000-0002-0151-1238
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Gusev, Alexander http://orcid.org/0000-0002-7980-4620
- License Information
-
More Information
Article History
Received: 5 April 2022
Accepted: 18 October 2022
First Online: 16 December 2022
Competing interests
: D.A.B. reports nonfinancial support from Bristol Myers Squibb, honoraria from LM Education/Exchange Services and personal fees from MDedge, Exelixis, Octane Global, Defined Health, Dedham Group, Adept Field Solutions, Slingshot Insights, Blueprint Partnerships, Charles River Associates, Trinity Group and Insight Strategy, outside of the submitted work. K.K. reports receiving honoraria from IBM and Roche. M.M.A. reports grants and personal fees from Genentech, grants and personal fees from Bristol Myers Squibb, personal fees from Merck, grants and personal fees from AstraZeneca, grants from Lilly and personal fees from Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, Gritstone, ArcherDX, Mirati, NextCure, Novartis, EMD Serono and Panvaxal/NovaRx, outside the submitted work. O.R. reports research support from Merck. He is speaker for activities supported by educational grants from Bristol Myers Squibb and Merck; consultant for Merck, Celgene, Five Prime, GSK, Bayer, Roche/Genentech, Puretech, Imvax, Sobi and Boehringer Ingelheim; and has a patent pending for ‘Methods of using pembrolizumab and trebananib’. S.A.S. reports nonfinancial support from Bristol Myers Squibb and equity in Agenus, Agios Pharmaceuticals, Breakbio Corp., Bristol Myers Squibb and Lumos Pharma. T.K.C. reports research/advisory board/consultancy/honoraria (institutional and personal, paid and unpaid) from AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, GSK, IQVA, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis and Takeda, Tempest; travel, accommodation, expenses and medical writing in relation to consulting, advisory roles or honoraria; stock options in Pionyr, Tempest, Osel and Recede Bio; UpToDate royalties for CME-related events (for example, OncLive, PVI, MJH Life Sciences) honoraria; National Cancer Institute Genitourinary Steering Committee, American Society of Clinical Oncology and European Society of Medical Oncology; patents filed, royalties or other intellectual property (no income as of current date) related to biomarkers of immune checkpoint blockers and circulating tumor DNA. Z.B. reports research support from the imCORE Network on behalf of Genentech and Bristol Myers Squibb and honoraria from UpToDate. A.G., T.K.C. and M.L.F. are inventors on a patent related to germline predictors of irAEs. The other authors declare no competing interests.
